Evidence map›Paper›PMID 24643650›Full record

ReviewCancer2014

State-of-the-science of patient navigation as a strategy for enhancing minority clinical trial accrual.

Rahel G Ghebre, Lovell A Jones, Jennifer A Wenzel, Michelle Y Martin, Raegan W Durant, Jean G Ford

Open access · bronzeAbstract readReview
In one paragraph

Review in Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 65 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Fecal transplantation for treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2023
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Rahel G GhebreDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, Minnesota.
Lovell A Jones
Jennifer A Wenzel
Michelle Y Martin
Raegan W Durant
Jean G Ford
University of Alabama at Birmingham · USBrooklyn Hospital Center · USJohns Hopkins University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Minnesota · US

Funding

Research Education CoreP30AG031054 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CROWTHER, MARTHA R · 2007 to 2025
$11.6M
Enhancing Minority Participation in Clinical Trials (EMPaCT):Phase IIU24MD006970 · NIMHD · UNIVERSITY OF MINNESOTA · PI DURANT, RAEGAN WINSTON, FOUAD, MONA N. · 2011 to 2015
$4.9M
Enhancing Minority Participation in Clinical Trials (EMPaCT)RC2MD004797 · NIMHD · UNIVERSITY OF MINNESOTA · PI FOUAD, MONA N., VICKERS, SELWYN M · 2009 to 2010
$4.2M
NIA NIH HHS P30 AG031054NIMHD NIH HHS RC2 MD004797NIMHD NIH HHS U24 MD006970
6 · The paper itself

Abstract

backgroundPatient navigation programs are emerging that aim to address disparities in clinical trial participation among medically underserved populations, including racial/ethnic minorities. However, there is a lack of consensus on the role of patient navigators within the clinical trial process as well as outcome measures to evaluate program effectiveness.

methodsA review of the literature was conducted of PubMed, Medline, CINHAL, and other sources to identify qualitative and quantitative studies on patient navigation in clinical trials. The search yielded 212 studies, of which only 12 were eligible for this review.

resultsThe eligible studies reported on the development of programs for patient navigation in cancer clinical trials, including training and implementation among African Americans, American Indians, and Native Hawaiians. A low rate of clinical trial refusal (range, 4%-6%) was reported among patients enrolled in patient navigation programs. However, few studies reported on the efficacy of patient navigation in increasing clinical treatment trial enrollment.

conclusionsOutcome measures are proposed to assist in developing and evaluating the efficacy and/or effectiveness of patient navigation programs that aim to increase participation in cancer clinical trials. Future research is needed to evaluate the efficacy of patient navigators in addressing barriers to clinical trial participation and increasing enrollment among medically underserved cancer patients.

Indexed as

Minority GroupsPatient SelectionBlack or African AmericanClinical Trials as TopicEthnicityHealthcare DisparitiesHealth Services AccessibilityHumansIndians, North AmericanNative Hawaiian or Pacific IslanderNeoplasmsPatient Acceptance of Health CarePatient Education as TopicPatient NavigationRacial GroupsResearch Designclinical trialdisparitiesminority healthneoplasmpatient navigation

Identifiers

PMID24643650
PMCPMC4039342
OpenAlexW2126024508

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.